Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/8/2013

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast- 2Q Fiscal Year 2013 Financial Results Press Release

2/14/2013 at 7:30 a.m. ET- 2Q Fiscal Year 2013 Conference Call-Live

2/14/2013 at 11:00 a.m. ET  Domestic Dial-In Number

1-888-539-3678  International Dial-In Number

1-719-325-2329  Passcode

4795478- 2Q Fiscal Year 2013 Conference Call-Replay

2/14/2013-2/21/2013  Domestic Dial-In Number

1-888-203-1112  International Dial-In Number

1-719-457-0820  Passcode

4795478  Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
2. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
4. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
8. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
11. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mar 23, 2017 Research and Markets ... Markets" report to their offering. ... The Global Market for ... in 2016 at a CAGR of 8.9%, ... non-energetic bioproducts into seven major product segments: bio-derived chemicals, biofuels, ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):